Standout Papers
Citation Impact
Citing Papers
Long-term recovery from unawareness, deficient counterregulation and lack of cognitive dysfunction during hypoglycaemia, following institution of rational, intensive insulin therapy in IDDM
1994
Liraglutide efficacy and action in non-alcoholic steatohepatitis (LEAN): study protocol for a phase II multicentre, double-blinded, randomised, controlled trial
2013
Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis
2013
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
2012 Standout
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Collaborative Care for Patients with Depression and Chronic Illnesses
2010
Bacterial Metabolite Indole Modulates Incretin Secretion from Intestinal Enteroendocrine L Cells
2014
Use and Abuse of HOMA Modeling
2004 Standout
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
2016 Standout
Thiazolidinediones
2004 Standout
Acromegaly
2006 Standout
Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes
2010
Complementing Insulin Therapy to Achieve Glycemic Control
2013
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
2016 Standout
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: An interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials
2007
Microbial tryptophan catabolites in health and disease
2018 Standout
Chronic inflammation in the etiology of disease across the life span
2019 Standout
Effects of Glucagon-Like Peptide 1 on Counterregulatory Hormone Responses, Cognitive Functions, and Insulin Secretion during Hyperinsulinemic, Stepped Hypoglycemic Clamp Experiments in Healthy Volunteers
2002
N6-methyladenosine Modulates Messenger RNA Translation Efficiency
2015 Standout
Prandial Premixed Insulin Analogue Regimens Versus Basal Insulin Analogue Regimens in the Management of Type 2 Diabetes: An Evidence-Based Comparison
2007
A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes
2008
Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial
2012
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
2015 Standout
Hypoglycemic Disorders
1995
The Treat-to-Target Trial and Related Studies
2006
Long-acting insulin analogues versus NPH human insulin in type 2 diabetes
2008
Comparison between Six-Year Therapy with Long-Acting Somatostatin Analogs and Successful Surgery in Acromegaly: Effects on Cardiovascular Risk Factors
2006
Efficacy of Anti Hyperglycemic Therapies and the Influence of Baseline Hemoglobin A1C: A Meta-Analysis of the Liraglutide Development Program
2011
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
2010
Hypoglycemia in Type 1 Diabetes Mellitus
2004
Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes
2007
Incretin-Based Therapies: Review of Current Clinical Trial Data
2010
Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study
2012 Standout
Mechanisms of NAFLD development and therapeutic strategies
2018 Standout
Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors
2010
The safety profile of exogenous insulin in people with type 2 diabetes: justification for concern
2011
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
2006 Standout
Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus
2008
Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study
2019 Standout
Liraglutide for the Treatment of Type 2 Diabetes Mellitus: A Meta-analysis of Randomized Placebo-Controlled Trials
2014
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
2012
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
2015 Standout
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
2006 Standout
Type 2 diabetes
2017 Standout
Effects of initiation and titration of a single pre‐prandial dose of insulin glulisine while continuing titrated insulin glargine in type 2 diabetes: a 6‐month ‘proof‐of‐concept' study
2011
Selective peroxisome proliferator-activated receptor γ (PPARγ) modulation as a strategy for safer therapeutic PPARγ activation
2009
Possible Role of Hydrogen Sulfide in Insulin Secretion and in Development of Insulin Resistance
2010
Polycystic Ovary Syndrome
2005 Standout
Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
2009
Polycystic ovarian syndrome and insulin resistance in white and Mexican American women: A comparison of two distinct populations
2002
PPARγ signaling and metabolism: the good, the bad and the future
2013 Standout
The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes: an overview of the LEAD 1–5 studies
2009
Subjective wellbeing, health, and ageing
2014 StandoutNobel
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
2010
Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2012 Standout
The Physiology of Glucagon-like Peptide 1
2007 Standout
Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes – focus on pancreatitis and pancreas cancer
2014
Synaptotagmin‐7 is a principal Ca2+ sensor for Ca2+‐induced glucagon exocytosis in pancreas
2009 StandoutNobel
The Discovery and Development of Liraglutide and Semaglutide
2019
Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
2015 Standout
Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: A multinational, randomized, open-label, two-period, crossover noninferiority trial
2007
Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes
2009
Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial
2019
Cardiovascular Effects of Glucagonlike peptide–1 Agonists
2011
Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes
1994
Insulin pump treatment compared with multiple daily injections for treatment of type 2 diabetes (OpT2mise): a randomised open-label controlled trial
2014
Insulin Resistance: A Metabolic Pathway to Chronic Liver Disease *
2005
Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications
2010
Hypoglycaemia: The limiting factor in the glycaemic management of Type I and Type II Diabetes*
2002
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
2015 Standout
Prediabetes: a high-risk state for diabetes development
2012 Standout
New Insulins and New Aspects in Insulin Delivery
2015
Major microbiota dysbiosis in severe obesity: fate after bariatric surgery
2018
Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta‐analysis of the LEAD program
2012
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Pathophysiology of Human Visceral Obesity: An Update
2013 Standout
Physiological Implications of Hydrogen Sulfide: A Whiff Exploration That Blossomed
2012 Standout
From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
2009 Standout
Impact of the Metabolic Syndrome on Mortality From Coronary Heart Disease, Cardiovascular Disease, and All Causes in United States Adults
2004 Standout
Pilot study of liraglutide effects in non‐alcoholic steatohepatitis and non‐alcoholic fatty liver disease with glucose intolerance in J apanese patients (LEAN ‐J )
2014
Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome
2006 Standout
Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus
2007
Mechanisms of Insulin Action and Insulin Resistance
2018 Standout
Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration
2015 Standout
Type 2 diabetes: principles of pathogenesis and therapy
2005 Standout
Advanced Glycation End Products
2006 Standout
α-Cells of the Endocrine Pancreas: 35 Years of Research but the Enigma Remains
2007
Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline
2008
Avoidance of Hypoglycemia Restores Hypoglycemia Awareness by Increasing β-Adrenergic Sensitivity in Type 1 Diabetes
2001
A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes
2006
A Common Polymorphism in the Promoter of UCP2 Contributes to the Variation in Insulin Secretion in Glucose-Tolerant Subjects
2003
Insulin detemir versus insulin glargine for type 2 diabetes mellitus
2011
An Accurate Risk Score Based on Anthropometric, Dietary, and Lifestyle Factors to Predict the Development of Type 2 Diabetes
2007
Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes
2005
The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases
2017 Standout
Delayed Recovery of Cognitive Function Following Hypoglycemia in Adults With Type 1 Diabetes
2007
Hypoglycemia in diabetes.
2003
Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes
2005
Once-Weekly Semaglutide in Adults with Overweight or Obesity
2021 Standout
International Diabetes Center Treatment of Type 2 Diabetes Glucose Algorithm
2011
Expression of Adiponectin Receptor mRNA in Human Skeletal Muscle Cells Is Related to In Vivo Parameters of Glucose and Lipid Metabolism
2004
How Do Glucocorticoids Influence Stress Responses? Integrating Permissive, Suppressive, Stimulatory, and Preparative Actions*
2000 Standout
Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin
2013
Mitochondrial Dysfunction and Type 2 Diabetes
2005 StandoutScience
Fibrosis — A Common Pathway to Organ Injury and Failure
2015 Standout
Insulin Secretion and Action in Subjects With Impaired Fasting Glucose and Impaired Glucose Tolerance
2006
Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation
2004
Mechanisms of Diabetic Complications
2013 Standout
The Gly972Arg Polymorphism in the Insulin Receptor Substrate-1 Gene Contributes to the Variation in insulin Secretion in Normal Glucose-Tolerant Humans
2001
Addition of Thiazolidinedione or Exenatide to Oral Agents in Type 2 Diabetes: A Meta-Analysis
2008
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Triple Therapy in Type 2 Diabetes
2006
Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial
2015
Hypoglycemia and Diabetes: A Report of a Workgroup of the American Diabetes Association and The Endocrine Society
2013 Standout
Genetic Variants of FTO Influence Adiposity, Insulin Sensitivity, Leptin Levels, and Resting Metabolic Rate in the Quebec Family Study
2008
Initiate Insulin by Aggressive Titration and Education (INITIATE)
2007
Independent Pathways for Secretion of Cholesterol and Apolipoprotein E by Macrophages
1983 StandoutScienceNobel
Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes
2014
The Significance of Impaired Fasting Glucose Versus Impaired Glucose Tolerance
2003
Hepatic Insulin Clearance Is Closely Related to Metabolic Syndrome Components
2013
Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Patients With Type 2 Diabetes Treated With Metformin and a Sulfonylurea
2005
Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia
2012 Standout
Familial dysbetalipoproteinemia. Abnormal binding of mutant apoprotein E to low density lipoprotein receptors of human fibroblasts and membranes from liver and adrenal of rats, rabbits, and cows.
1981 StandoutNobel
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
2018 Standout
Acute Hyperglycemia Causes Intracellular Formation of CML and Activation of ras, p42/44 MAPK, and Nuclear Factor κB in PBMCs
2003
Consensus Statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the Comprehensive Type 2 Diabetes Management Algorithm – 2018 Executive Summary
2018
Hypoglycemia in Diabetes
2003
Familial Dysbetalipoproteinemia: New Aspects of Pathogenesis and Diagnosis
1982
Works of John Gerich being referenced
Matching treatment to pathophysiology in type 2 diabetes
2001
Reversibility of Unawareness of Hypoglycemia in Patients with Insulinomas
1993
IMPROVED GLUCOSE COUNTERREGULATION AND AUTONOMIC SYMPTOMS AFTER INTRAPORTAL ISLET TRANSPLANTS ALONE IN PATIENTS WITH LONG-STANDING TYPE I DIABETES MELLITUS1
1998
Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD)
2009
Use of the oral glucose tolerance test to assess insulin release and insulin sensitivity.
2000
Pancreatic Alpha and Beta Cell Function in Familial Dysbetalipoproteinemia
1980
The Treat-to-Target Trial
2003 Standout